Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. - Wikidata - wikimedia - TriplyDB

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

http://www.wikidata.org/entity/Q44761576

about

Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients Phosphate control in dialysis Vascular calcification: When should we interfere in chronic kidney disease patients and how?Fibroblast Growth Factor-23-A Potential Uremic Toxin Stop chronic kidney disease progression: Time is approaching Hyperphosphatemia. The hidden killer in chronic kidney disease Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.Efficacy and safety of nicotinamide in haemodialysis patients: the NICOREN study.Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial.Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart calcium Pharmacology, efficacy and safety of oral phosphate binders.Intestinal phosphate transport.Water-soluble vitamins in people with low glomerular filtration rate or on dialysis: a review Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.Npt2b deletion attenuates hyperphosphatemia associated with CKD.Treatment of phosphate retention: The earlier the better?Phosphate binders: new products and challenges.The safety of phosphate binders.A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.Effect of low dose nicotinic acid on hyperphosphatemia in patients with end stage renal disease.Use of nicotinamide to treat hyperphosphatemia in dialysis patients.Investigation of gender heterogeneity in the associations of serum phosphorus with incident coronary artery disease and all-cause mortality.Hepatectomy-related hypophosphatemia: a novel phosphaturic factor in the liver-kidney axis.Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients.Phosphate homeostasis and the renal-gastrointestinal axis.Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.Intestinal phosphate transport: a therapeutic target in chronic kidney disease and beyond?Contemporary management of phosphorus retention in chronic kidney disease: a review.Regulation of renal phosphate handling: inter-organ communication in health and disease.Advances in pharmacotherapy for hyperphosphatemia in renal disease.Definition of a tolerable upper intake level of niacin: a systematic review and meta-analysis of the dose-dependent effects of nicotinamide and nicotinic acid supplementation.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Nicotinamide and phosphate homeostasis in chronic kidney disease.Oral peptide specific egg antibody to intestinal sodium-dependent phosphate co-transporter-2b is effective at altering phosphate transport in vitro and in vivo.The effect of niacin on serum phosphorus levels in dialysis patients.

P2860

Q27006968-0B618C94-1509-4F39-A95D-521E09849E7C Q27025339-CA863B97-5D28-469A-BF32-EE8036EFFE0A Q28071582-E5881064-410B-46DC-822B-4B72F2DDEE75 Q28075648-D3F094DD-B04D-4A35-920F-4C68E9AB1630 Q28078020-BD8EDA00-F1BC-4159-AC93-BF6C21D47B19 Q28081229-BB43A12C-15B6-4B87-A4BC-625DACFDEB95 Q33410839-20EFAACD-27EB-4A2D-9B0D-C6992B82C26F Q33432308-4976E4F5-9DBA-4B18-871D-289E8A848667 Q33770086-AFF4B83E-DCB0-47B5-8336-E6E8069F2F1E Q33937415-B4BC8346-893D-4AF4-BC46-AC69B6537C41 Q34147642-A0F9E980-0817-4B2C-B844-CE9905DEBEA7 Q34213752-E2ACE425-9669-470A-8EFC-4D1F1D56E7BD Q34768129-5D3B7459-E2C8-4E72-955A-DBAC02423497 Q34852823-FB7CB2B9-E85C-48FB-B3AD-F2294181AA3A Q35351243-9AA33DA2-6844-4292-A8D1-B03503130670 Q36104887-28812AF6-2FAF-4B53-B0A1-5E72C9595210 Q36280326-DA4B3A48-1194-49B3-B9F9-01185132B2DB Q36466010-D66A0B87-44CD-43CD-812C-D12360C3738C Q36522027-9429A5F2-02FD-4DF4-8171-09B8E4656358 Q36565049-D1AE382C-589C-407D-BFA3-A284594A8536 Q36736674-5BBEFF81-8CBF-4C12-BC39-7B10A6090E07 Q37099010-A72B96C7-7FAB-49E3-8F45-4A8AD0D9C06C Q37135110-05218043-B69A-4718-B879-32EBFEDBD863 Q37199788-6E17A049-93D2-42EB-9F30-88DCC1D53B4B Q37288856-EF6F46C1-9B2A-4769-9938-DBFB4E84810C Q37670328-B6A3BBEA-22E9-49E1-AE32-9EA06362D517 Q37673251-DEE263B4-B4AB-476E-BD0D-7FAABBC48D57 Q37763810-E2EC4739-A5C9-4591-9B0F-6E4B15E5206C Q38011204-567E6334-BC0A-42F8-9B91-92C5091BF5D2 Q38092144-3C6AB559-2A27-48B4-AA30-7AB562593698 Q38092792-87C5DD49-429B-4CFB-9005-7F55D7D487E9 Q38185277-4ED609A8-7426-4859-BF78-853B0A083AE7 Q38511621-293B363B-8101-483F-9BFF-0540A30ABD27 Q38571301-42BD1109-C915-40F7-9B59-5C318A6F3947 Q38587575-5DF8886C-7355-443C-93E0-F42D9D7E36BA Q38765419-E626114B-AA78-49F4-AEC8-C9172E5B461E Q38828902-8D5829CC-D3AF-49C2-9A3E-460D97BF3C85 Q38842982-E13BFC57-577C-498F-8D6E-96BA1F50D73A Q38892733-9B5CF8A7-EF5F-452F-BAD0-77FAAF93CE98 Q42585296-888EC2F2-D1DC-4D78-8197-3A69ED20F3B8

P2860

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

http://www.wikidata.org/entity/Q44761576

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

@en

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

@nl

type

label

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

@en

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

@nl

prefLabel

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

@en

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

@nl

P1433

Q44761576-280E8B4F-4500-4AE6-BBCF-AAA16B3655C5

P1476

Q44761576-7B80E828-B660-4449-80BF-E864F40E6DCD

P2093

Q44761576-06C17D22-C05E-4E0D-B77A-7A99A9E261CD

Q44761576-45DCAD33-D10B-470D-AC6E-AF354EB436C6

Q44761576-4D864BC6-234D-4D90-A896-220F5BCBC51C

Q44761576-71460B1F-23D4-4735-8480-FD19FBC78D9D

Q44761576-74F5504F-1ABF-42A3-8FA8-D2EA63762848

Q44761576-D60AA6F6-DC25-4C56-942B-F05771E707F3

Q44761576-E168D7F4-CB4A-4E93-8A69-25B1BEB521EF

Q44761576-E49B7364-70DA-4039-AF40-97EB727EB3CE

P2888

Q44761576-EFABF6AD-9567-4352-BC87-860ECD691903

P304

Q44761576-46A77900-C38D-47FA-8A2C-E884CAB1C17B

P31

Q44761576-87360AF6-B075-415A-9E61-58308E2F76DF

P356

Q44761576-5BA7E498-4FBB-46D9-A590-9F96AFE483DF

P407

Q44761576-1707B642-95AA-4465-A70C-7662E1BAE8AF

P433

Q44761576-A815FE42-AC17-473C-9107-3BFA9D369941

P478

Q44761576-8BEDCD6F-451F-40D1-BEE1-D1EA51B8CEA7

P577

Q44761576-AE4218F1-3498-4619-996F-48F902FD114C

P5875

Q44761576-F3D18AE3-E5C1-4407-B939-90653582288F

P6179

Q44761576-537D8416-C8BC-4B1A-989F-2490CF08DB0F

P698

Q44761576-713594DA-390D-43A9-ABD8-635FD8034B34

P921

Q44761576-037AD201-AF66-4AFA-8A87-F1F24B9DFA37

P356

J.1523-1755.2004.00482.X

P1433

Kidney International

P1476

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.

@en

P2093

Araki Tanaka

http://www.w3.org/2001/XMLSchema#string

Hikaru Koide

http://www.w3.org/2001/XMLSchema#string

Isao Ebihara

http://www.w3.org/2001/XMLSchema#string

Katsumi Shibata

http://www.w3.org/2001/XMLSchema#string

Noriaki Shimada

http://www.w3.org/2001/XMLSchema#string

Tsukasa Nakamura

http://www.w3.org/2001/XMLSchema#string

Tsutomu Fukuwatari

http://www.w3.org/2001/XMLSchema#string

Yutaka Takahashi

http://www.w3.org/2001/XMLSchema#string

P2888

j.1523-1755.2004.00482.x

P304

1099-1104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1523-1755.2004.00482.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8779765

http://www.w3.org/2001/XMLSchema#string

P6179

1036526364

http://www.w3.org/2001/XMLSchema#string

P698

14871431

http://www.w3.org/2001/XMLSchema#string

P921